The cost of waiting: ADHD, early death and assessment rationing

Waiting lists are usually discussed as an inconvenience. New research suggests that for ADHDers, they are a question of risk. A meta-analysis published in JAMA Network Open links ADHD to a 70% higher risk of early death from any cause. In England, meanwhile, a growing number of NHS areas are rationing ADHD assessment, some with minimum waits of two years. Put side by side, those two facts should change how we talk about waiting.

Content note: this post discusses suicide. Support details are at the end.

What The Research Found

The review, published on 19 October 2026, was led by researchers at the University of Liverpool and UCL, with colleagues from King’s College London and ADHD UK. They brought together 19 studies covering more than 15.9 million people in seven countries, some following participants for over 20 years.

The all-cause figure draws on nine studies; each specific cause draws on three to five. Among ADHDers, those taking ADHD medication had around a 25% lower risk of death, although this rests on only three studies.

The senior author, Professor Joshua Stott, put the central point plainly: “ADHD is not by definition a life-limiting condition.” The right support and treatment, he said, can help ADHDers live long and healthy lives.

2. Reading the numbers carefully

Figures like these travel fast, so it is worth being precise about what they do and do not say.

• They are relative, not personal. A 70% higher rate does not mean a 70% chance of dying. Roughly, for every 100 deaths in a comparable group without ADHD, about 170 would be expected among ADHDers.
• They show association, not cause. Every study was observational. The review cannot show that ADHD itself causes these deaths, or that medication prevents them; people who access medication may also have better access to care and more resources.
• The studies vary widely. Results differed sharply between countries and health systems. Many samples were mostly male, which may hide risks specific to women, and some people may be counted more than once across national databases.

2.1 Where the risk comes from

The researchers do not locate the risk in ADHD alone. They point to higher rates of mental distress, stigma, social exclusion and disadvantage, alongside barriers to healthcare and higher rates of physical illness. Health risk behaviours such as smoking and alcohol use are part of the picture too.

That matters. A finding framed as “ADHD kills” invites fear and blame. Read properly, this is evidence about what happens when ADHDers live in systems that are not built for them, and are then left to wait for help.

3. Rationing in England

This evidence lands at a time when access to ADHD assessment in England is shrinking, not growing. An analysis by Finally Seen, reported by The BMJ, found nearly half of England’s integrated care boards (ICBs) have introduced rationing for ADHD and autism assessments.

• 15 ICBs, covering 19 million people, now use some form of rationing.
• Four (West Yorkshire; North East and North Cumbria; Somerset; Devon) have imposed two-year minimum waits for adults and children.
• Others use “clinical prioritisation” to restrict assessment to people with the most severe presentations.

Charities called the measures scandalous, warning that delays could raise suicide risk and damage children’s chances at school. (Finally Seen supports people challenging NHS restrictions on their right to choose a provider.) Adult NHS ADHD assessment waits are already commonly reported at three to six years.

Rationing is usually presented as a way to manage demand. The new mortality evidence asks a harder question: when a two-year minimum wait is imposed, who carries the risk of that wait? The answer is ADHDers, and the people who love them.

4. A different model: New South Wales

On 21 October, the New South Wales government in Australia set out a very different response to the same pressures. Almost 300 GPs have completed training to assess and diagnose ADHD and start medication, with a further 300 beginning next month.

• Specialist backing: GPs are supported by psychiatrists and paediatricians through a virtual hub, and can still refer on when needed.
• Earlier progress: nearly 1,700 GPs were already trained to continue ADHD medication; more than 25,000 people have accessed medication more easily, filling over 130,000 prescriptions.
• Funding: an A$11.7 million package, including up to 2,500 free GP assessments and support for specialist services.
• Fairness by design: the first 300 GPs were prioritised in rural and regional areas.

The state’s Minister for Mental Health, Rose Jackson, said a diagnosis “shouldn’t depend on how much money your family has or where you live.”

Australia’s health system is not England’s, and GP-led diagnosis is not a complete answer on its own. But the contrast makes one thing clear: capacity is a policy choice. Faced with rising demand, one government is building access; parts of the NHS are closing it.

5. What needs to change

At NeuroHub Community, we believe access to assessment and support is a matter of rights, not rationing. This research strengthens five calls.

1. Count the cost of waiting. ICBs should publish ADHD and autism waiting times, and assess the harm of any rationing decision, including suicide risk, before imposing it. Blanket minimum waits should end.
2. Support should not wait for a diagnosis. Mental health support, crisis planning and reasonable adjustments at school and work should be available from the point of referral. That is what a genuinely needs-led system looks like.
3. Build capacity where people already are. Fund GP and community-based assessment with proper specialist backing, as New South Wales has done.
4. Tackle the structural drivers. The risk sits in exclusion, stigma and disadvantage, so prevention must start there; eg; ADHD-informed suicide prevention, accessible healthcare and non-judgemental harm reduction.
5. Design with ADHDers, not around them. Services and policy should be shaped by neurodivergent people from the start.

Waiting has never been neutral. With this evidence, it is much harder to pretend otherwise.

Support

If this post has raised difficult feelings, you do not have to hold them alone.

• Samaritans (UK and Ireland, 24 hours): call 116 123 or email jo@samaritans.org
• Shout (UK, 24 hours): text SHOUT to 85258

Sources

• Corrigan L, Heywood L, Stewart GR, O’Nions E, Shelford H, Stott J, John A. Mortality Among People With Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-Analysis. JAMA Network Open, 2026;9(10):e2639448.
• UCL study reveals broad mortality risks faced by ADHD individuals (UCL release via News-Medical, 19 October 2026)
• ADHD linked to 71% higher death risk, study finds (StudyFinds, 20 October 2026; study counts and limitations)
• ADHD and autism: two year minimum waits imposed in fresh NHS rationing drive (The BMJ)
• New ADHD and autism policy announced in Coventry and Warwickshire (Hits Radio, 18 May 2026; typical waiting times)
• Nearly 300 GPs trained to safely diagnose and treat ADHD (NSW Government, 21 October 2026)